Repeatability of Magnetic Resonance Imaging in Patients With IDH1 Mutant Glioma on Ivosidenib
Sponsored by Duke University
About this trial
Last updated 8 months ago
Study ID
PRO00116521
Status
Not yet recruiting
Type
Interventional
Phase
N/A
Placebo
No
Accepting
18 to 70 Years
All
Not accepting
Healthy Volunteers
Trial Timing
Started 6 months ago
What is this trial about?
The purpose of this study is to evaluate the repeatability of magnetic resonance imaging
(MRI) in patients with isocitrate dehydrogenase 1 (IDH1) mutant (mIDH1) low-grade diffuse
glioma [World Health Organization (WHO) grade 2] who are receiving off-label ivosidenib.
What are the participation requirements?
Inclusion Criteria
1. Written informed consent prior to beginning specific protocol procedures
2. Scheduled for contrast-enhanced magnetic resonance imaging (MRI) as part of clinical care
3. Histologically IDH1 mutant low-grade glioma (WHO grade 2) and actively receiving ivosidenib
4. Active patient treatment or evaluations at the Preston Robert Tisch Brain Tumor Center at Duke
5. Age ≥18 years and ≤70 years
6. Karnofsky performance index ≥70%
7. Primary treating physician approval
Exclusion Criteria
1. Inability to have MRIs